Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 702.98

-3.1%

Nov 19 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (2176)	1/3/2018 7:47:53 PM
From: Miljenko Zuanic	Read Replies (2) of 3559

<I checked REGN balance shits, and am happy that they improve it. Hope, it may stay that way. Eylea WW revenue will continue to increase in next few more years,...> Well, that "few years" may pass quickly, patents expire in 2023 (???, I think), and bio-similar to Eylea is on a way: globenewswire.com <Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)> I thought that it will be hard to do biosimilar to "TRAP", ....to follow progress of his program will be high on my list.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next